Nrx pharmaceuticals announces closing of $25 million private placement priced at a premium to market under nasdaq rules

Radnor, pa., feb. 2, 2022 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp (or the "company"), a delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market under nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock.
NRXP Ratings Summary
NRXP Quant Ranking